Tumor ablation refers to a group of minimally invasive techniques used to destroy tumor tissue directly, typically through the application of extreme heat or cold rather than surgical removal or systemic drug therapy. These percutaneous ablation techniques are guided by imaging — commonly ultrasound, CT, or MRI — allowing physicians to place a probe or applicator precisely within a tumor while avoiding critical surrounding structures. Tumor ablation is used across a range of tumor types and locations, including liver, kidney, lung, and bone lesions, often in patients who may not be candidates for traditional surgical resection. This article provides a general overview of the three most commonly discussed ablation modalities: radiofrequency, microwave, and cryoablation.
What Is Image-Guided Ablation and How Is It Performed?
Image-guided therapy for tumor ablation typically involves inserting a thin probe or needle-like applicator through the skin and into the tumor under continuous or intermittent imaging guidance. Once positioned, the probe delivers energy — heat in the case of radiofrequency and microwave systems, or extreme cold in the case of cryoablation — to destroy the targeted tissue through a process called coagulative necrosis (for heat-based methods) or cell death from freezing (for cryoablation). Because the procedure is percutaneous, it generally involves a smaller incision and shorter recovery compared with open surgical resection, though it is not appropriate for every tumor type, size, or location. Whether percutaneous ablation is a suitable option for a specific tumor is determined by a multidisciplinary care team based on tumor characteristics, location, and the patient's overall clinical picture.
How Does Radiofrequency Ablation (RFA) Destroy Tumor Tissue?
Radiofrequency ablation uses high-frequency alternating electrical current delivered through an electrode placed within the tumor. This current generates frictional heat within the tissue surrounding the electrode, raising the local temperature to levels that cause coagulative necrosis of the targeted cells. RFA systems typically monitor tissue impedance and temperature during the procedure to help guide energy delivery and manage the size of the ablation zone. Electrode designs vary, including single needle electrodes and expandable multi-tine arrays intended to treat larger tumor volumes. RFA is commonly discussed in the context of treating hepatocellular carcinoma, renal tumors, and certain bone or soft-tissue lesions where percutaneous therapy is considered appropriate.
What Distinguishes Microwave Ablation From Other Heat-Based Methods?
Microwave ablation (MWA) also generates heat to destroy tumor tissue, but it does so using electromagnetic microwave energy rather than electrical current passed through tissue. This energy source is generally associated with the ability to reach higher temperatures more quickly and, in some cases, to produce a larger ablation zone per probe compared with radiofrequency systems, according to general interventional oncology literature. Microwave ablation is less dependent on tissue electrical conductivity than RFA, which some clinicians associate with more predictable heating near blood vessels, where flowing blood can otherwise carry heat away from the treatment zone. As with RFA, suitability for microwave ablation depends on tumor size, location, and characteristics assessed by the treating physician.
How Does Cryoablation Differ From Heat-Based Ablation Modalities?
Cryoablation takes the opposite thermal approach, using one or more probes to deliver extremely cold temperatures that freeze the targeted tissue, forming what is commonly called an "ice ball" around the probe tip. Tumor cell destruction occurs through mechanisms including direct cellular injury from ice crystal formation and vascular effects during repeated freeze-thaw cycles. Cryoablation is frequently discussed in the treatment of renal tumors and certain other lesions, partly because the ice ball can often be visualized directly on imaging during the procedure, which some clinicians find useful for confirming treatment margins. As with heat-based modalities, appropriateness of cryoablation is determined on a case-by-case basis by the treating care team.
Choosing Between Ablation Modalities: What Factors Matter?
No single ablation modality is universally preferable; radiofrequency, microwave, and cryoablation each have characteristics that may make them more or less suitable for a particular tumor. Factors commonly considered include tumor size and location, proximity to blood vessels or sensitive structures, the underlying tumor type, and physician experience with a given technology. Because these factors vary significantly between patients, the choice of ablation modality is a clinical decision made collaboratively between the interventional radiologist, oncologist, and patient, based on the specific case.
Is tumor ablation a substitute for surgery?
Tumor ablation is sometimes used as an alternative to surgical resection, particularly for patients who are not surgical candidates or who have smaller, well-localized tumors, but it is not a universal substitute for surgery in all cases. Whether ablation, surgery, or another treatment approach is appropriate depends on tumor characteristics, location, and the patient's overall health. This determination is made by a multidisciplinary care team, not through self-selection of a treatment method.
What happens to tumor tissue after ablation?
Ablated tissue undergoes necrosis and is generally not surgically removed; instead, the body gradually reabsorbs or scars the treated area over time. Follow-up imaging is typically used to assess the treated zone and monitor for any residual or recurrent tumor tissue. The specific follow-up schedule and imaging approach are determined by the treating physician based on the tumor type and initial treatment response.
Are there risks associated with percutaneous tumor ablation?
As with any medical procedure, percutaneous ablation carries risks, which can include bleeding, infection, injury to nearby structures, or incomplete treatment of the tumor. These risks vary depending on tumor location, size, and patient-specific factors. Patients should discuss the full risk profile relevant to their individual case with their treating physician before undergoing any ablation procedure.
For an overview of ablation systems, see the oncology-ablation products category.
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.